Valuation : Innoviva, Inc.

Market Cap 1.49B 1.29B 1.22B 1.1B 2.07B 143B 2.08B 14.46B 5.56B 72.47B 5.61B 5.48B 229B P/E 2026 *
9.6x
P/E 2027 * 8.87x
Enterprise Value 1.06B 915M 866M 785M 1.47B 101B 1.48B 10.27B 3.95B 51.5B 3.98B 3.9B 163B EV / Sales 2026 *
2.38x
EV / Sales 2027 * 1.76x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week-3.14%
Current month-0.53%
1 month-0.43%
3 months-7.93%
6 months-7.85%
Current year+3.35%
1 week 20.45
Extreme 20.45
21.51
1 month 20.45
Extreme 20.45
21.7
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 2020-05-19
Director of Finance/CFO 60 2023-08-20
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 2018-02-11
Director/Board Member 66 2018-02-11
Director/Board Member 42 2025-05-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Tax

Controller/Auditor

-1,127 0.0015%
8/20/26 Tax

Chief Executive Officer

-1,130 0.0015%
8/20/26 Tax

Chief Financial Officer

-558 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-3.14%+6.33%+65.28% 1.49B
-0.65%-2.93%+47.52%+87.34% 994B
-0.29%-3.51%+48.78%+63.27% 640B
+0.83%+0.26%+16.76%+72.52% 454B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
Average -0.64%-5.50%+19.10%+43.35% 350.63B
Weighted average by Cap. -0.51%-4.42%+29.86%+55.72%

Financials

2026 *2027 *
Net sales 447M 385M 364M 330M 619M 42.66B 623M 4.32B 1.66B 21.68B 1.68B 1.64B 68.57B 489M 421M 399M 361M 678M 46.69B 682M 4.73B 1.82B 23.73B 1.84B 1.79B 75.04B
Net income 175M 151M 143M 130M 243M 16.74B 244M 1.7B 652M 8.51B 658M 643M 26.9B 183M 158M 150M 136M 254M 17.52B 256M 1.78B 683M 8.9B 689M 673M 28.16B
Net Debt -432M -373M -353M -320M -599M -41.27B -603M -4.18B -1.61B -20.97B -1.62B -1.59B -66.33B -631M -544M -515M -467M -875M -60.27B -880M -6.11B -2.35B -30.63B -2.37B -2.32B -96.86B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
159
Date Price Change Volume
26-09-11 US$20.66 +0.19% 727,347
26-09-10 US$20.62 -2.41% 836,382
26-09-09 US$21.13 -0.98% 847,360
26-09-08 US$21.34 +0.05% 782,828
26-09-04 US$21.33 -0.09% 563,508
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
20.66USD
Average target price
35.00USD
Spread / Average Target
+69.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!